Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pulmonology
•
Journal Club ft. NEJM publications
•
Obstructive Lung Disease
•
COPD
Did the low rate of COPD exacerbations in the BOREAS cohort overall confound the results of the study?
Answer from: at Community Practice
I feel that the results are still very impressive despite this.
Sign in or Register to read more
Answer from: at Academic Institution
They met their primary and secondary endpoints. So while data might be more robust, dupilumab impacted the study.
Sign in or Register to read more
19098
19144
Related Questions
Will you use FeNO testing in all COPD patients to determine whether they are candidates for therapy with dupilumab?
What patient factors prompt you to consider starting dupilumab in patients with COPD?
Are the results of the BOREAS trial generalizable to non-white populations?
Have you implemented the Rome proposal for COPD exacerbations?
Do you use hypercapnia as an exclusion criteria in all patients that are being assessed for bronchoscopic lung volume reduction?
Can recurrent bilateral nasal polyps be attributed to untreated ABPA?
Do you prescribe bronchodilators to patients with radiographic emphysema and respiratory symptoms, but no spirometric obstruction?
What is your approach to inhaler therapy in a patient with asthma who cannot be on an inhaled corticosteroid due to ocular disease?
Do you use continuous or intermittent bronchodilator therapy in severe airway obstruction?
Is methacholine challenge on its way out?